title: Fluoride controlled release tablets for intrabuccal use.
abstract: We have developed a fluoride controlled release delivering system for intrabuccal use, permitting to reach high enough local concentrations for desirable therapeutic effect with minimal side effects. We have formulated tablets of 160-200mg intended to be fixed on a tooth. The tablets have a granular matrix composed of pure hydroxyapatite, Eudragit((R)) and/or ethylcellulose. NaF is added either by a mechanical mixing or an impregnation method. Profiles of continuous in vitro drug release in saline phosphate buffered solution were recorded by means of a fluoride selective electrode. Linear profiles are observed when ethylcellulose is used. The most reproducible results are obtained when the impregnation method is used. Eudragit((R)) increases the dissolution efficiencies while ethylcellulose decreases it.
authors.affiliation: Laboratoire de Physique, Faculté de Médecine et de Pharmacie, Université Cheikh Anta Diop, DAKAR, Senegal.
authors.forename: M
authors.initials: M
authors.lastname: Diarra
authors.forename: G
authors.initials: G
authors.lastname: Pourroy
authors.forename: C
authors.initials: C
authors.lastname: Boymond
authors.forename: D
authors.initials: D
authors.lastname: Muster
mesh_terms: D000278:Administration, Buccal; D001672:Biocompatible Materials / Q000737:chemistry*; D003692:Delayed-Action Preparations; D016503:Drug Delivery Systems; D015195:Drug Design; D017886:Durapatite / Q000737:chemistry*; D012969:Sodium Fluoride / Q000008:administration & dosage*; D013607:Tablets / Q000008:administration & dosage
chemical_list: D001672:Biocompatible Materials; D003692:Delayed-Action Preparations; D013607:Tablets; D012969:Sodium Fluoride; D017886:Durapatite